Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG Fluorescence Imaging in Benign Bone Tumors
NCT05075889Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in benign bone tumor, sponsored by Dartmouth Health. Primary endpoint: Fluorescent intensity contrast. Started Nov 2021; status: completed.
02
Drugs
indocyanine green
03
Conditions
benign bone tumor
Beyond the preview
Go deeper on NCT05075889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075889.